PDF(Pubmed)
Abstract：
Inflammatory skin diseases highlight inflammation as a central driver of skin pathologies, involving a multiplicity of mediators and cell types, including immune and non-immune cells. Adenosine, a ubiquitous endogenous immune modulator, generated from adenosine triphosphate (ATP), acts via four G protein-coupled receptors (A1, A2A, A2B, and A3). Given the widespread expression of those receptors and their regulatory effects on multiple immune signaling pathways, targeting adenosine receptors emerges as a compelling strategy for anti-inflammatory intervention. Animal models of psoriasis, contact hypersensitivity (CHS), and other dermatitis have elucidated the involvement of adenosine receptors in the pathogenesis of these conditions. Targeting adenosine receptors is effective in attenuating inflammation and remodeling the epidermal structure, potentially showing synergistic effects with fewer adverse effects when combined with conventional therapies. What is noteworthy are the promising outcomes observed with A2A agonists in animal models and ongoing clinical trials investigating A3 agonists, underscoring a potential therapeutic approach for the management of inflammatory skin disorders.
摘要：
炎症性皮肤病突出显示炎症是皮肤病的主要驱动因素，涉及多种介质和细胞类型，包括免疫细胞和非免疫细胞。腺苷,一种普遍存在的内源性免疫调节剂，三磷酸腺苷（ATP），通过四个G蛋白偶联受体(A1，A2A，A2B,和A3）。鉴于这些受体的广泛表达及其对多种免疫信号通路的调节作用，靶向腺苷受体是一种引人注目的抗炎干预策略.银屑病动物模型,接触性超敏反应（CHS），和其他皮炎已经阐明了腺苷受体在这些疾病的发病机理中的参与。靶向腺苷受体在减轻炎症和重塑表皮结构方面是有效的，与常规疗法联合使用时，可能显示出协同作用，不良反应较少。值得注意的是A2A激动剂在动物模型和正在进行的研究A3激动剂的临床试验中观察到的有希望的结果。强调治疗炎症性皮肤病的潜在治疗方法。
